Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction
© Yang et al.; licensee BioMed Central Ltd. 2014
Received: 9 May 2013
Accepted: 13 December 2013
Published: 7 January 2014
Although immune dysfunction plays a role in the pathogenesis of systemic sclerosis (SSc), involvement of T helper 17 (Th17) and T regulatory (Treg) cells remains unclear. We aimed to investigate the presence of Th17 and Treg cells in SSc patients and the role of Th17 cells in collagen production in SSc fibroblasts.
We analyzed inflammatory cell profiles in the skin of 13 SSc patients by immunohistochemistry, the percentage of Th17 and Treg cells in peripheral blood mononuclear cells (PBMCs) of 45 SSc patients and 24 healthy controls by flow cytometry, gene expression in PBMCs by real-time reverse transcription-polymerase chain reaction and interleukin-17 (IL-17) in sera and culture supernatants by enzyme-linked immunosorbent assay. We also investigated the effect of Th17 cell-derived IL-17 on fibroblast growth and collagen production.
Infiltration of inflammatory cells including IL-17+ and Foxp3+ lymphocytes was detected in the skin of patients with early SSc. The percentages of circulating Th17 cells and IL-17 production were elevated in samples from patients with active SSc, whereas the percentage of circulating Treg cells was not affected. The number of Th17 cells was closely related to disease activity. IL-17 from SSc patients promoted fibroblast growth and collagen production, whereas IL-17 neutralizing antibody effectively blocked collagen production.
SSc progression might be linked to expansion of circulating Th17 cells and increased infiltration of IL-17+ cells in skin. Th17-derived IL-17 is involved in fibroblast growth and collagen production. IL-17 blocking antibody may be a useful tool for intervention in the fibrotic course of SSc.
Systemic sclerosis (SSc) is a complex inflammatory autoimmune disease characterized by excessive deposition of collagen that leads to fibrosis of multiple organs, including the skin, lungs, heart, and gastrointestinal tract, and is often associated with widespread vasculopathy and immunologic abnormalities.
A unique feature of SSc that distinguishes it from other fibrotic disorders is that autoimmunity and vasculopathy characteristically precede fibrosis. Although immunomodulatory drugs have been used extensively in the treatment of SSc, to date, no therapy has been able to reverse the progression of tissue fibrosis or substantially to modify the natural progression of the disease. This is mainly because the mechanisms responsible for the initiation and progression of the disease have not been clearly identified.
Growing evidence suggests that T-cell proliferation and cytokine secretion play a major role in the pathogenesis of SSc[2–4], suggesting that this condition could be associated with a general defect in the control of T-cell activation. Recently, a subset of T-helper cells was described and named T helper 17 (Th17) cells, based on their production of interleukin (IL)-17A, IL-17F, and IL-22[5, 6]. IL-17 concentration was reported to be elevated in the serum of SSc patients[7, 8]. This finding was further confirmed in more recent studies, which reported drastically increased proportions of Th17 cells in SSc patients[9–11]. Our previous study showed that Th17 cells are expanded in systemic lupus erythematosus (SLE) patients, and Th17 cell-derived IL-17 is related to recruitment of inflammatory cells to vascular endothelial cells; however, the role of Th17 cells and IL-17 in the fibrosis of SSc is not clear. Naturally occurring CD4 regulatory T (Treg) cells maintain immune balance and control the inflammatory injuries[13, 14]. It has been suggested that Th17 and Treg cells are produced in a reciprocal manner, depending on the levels of potentially proinflammatory or antiinflammatory cytokines and activation of specific transcription factors[15, 16]. Thus, we hypothesized that altered cytokine profiles in SSc patients might result in an imbalance of Th17/Treg cells, and might be responsible for the prominent features of SSc, such as fibroblast proliferation and endothelium injury[2, 17].
Here, we first demonstrated increased IL-17+ and Foxp3+ lymphocyte infiltration in the lesions of patients with early SSc. In detailed studies of circulating Th17 and Treg cells in 45 SSc patients, we showed that Th17 cells exhibited global expansion in peripheral blood rather than redistribution in vivo, and this expansion of Th17 cells was related to disease activity but was not correlated with Treg cell depletion during disease flare. Further studies demonstrated that IL-17 derived from patients with active SSc promoted fibroblast growth and collagen production, and neutralization of IL-17 could alleviate the production of collagen. These data suggest that the pathophysiology of SSc might be linked to the expansion of Th17 cells, and that Th17-derived IL-17 may play a key role in the fibrotic course of SSc.
SSc patients and healthy controls
This study was approved by the Ethical Committee of Zhongshan Hospital, Fudan University (Shanghai, People’s Republic of China). All SSc patients were referred to the Department of Dermatology at Zhongshan Hospital and all provided informed consent. Forty-five consecutive adult patients (36 women and nine men, mean age 50.9 ± 7.2 years) who met the American College of Rheumatology criteria for the classification of SSc were included in the study. Among these, 20 patients were classified as having limited cutaneous SSc (lSSc), and 25, as having diffuse cutaneous SSc (dSSc), according to the system proposed by Le Roy et al.. Disease activity was assessed by using the criteria proposed by Valentini et al., in which evaluation of clinical and laboratory factors results in a score ranging from 0 to 10 (0 represents no disease activity, and 10 represents maximal activity). Thirteen patients (nine women and four men, mean age, 48.4 ± 7.2 years) with a score ≥3 were classified as the active SSc group. The stable SSc group comprised 32 patients (27 women and five men, mean age, 51.9 ± 14.2 years) with score a <3. SSc patients were treated with prednisone, or cyclophosphamide + prednisone.
For the control group, 24 age- and sex-matched healthy individuals (18 women and six men, mean age, 50 ± 9.2 years) were enrolled after providing informed consent.
For histochemistry analysis, skin tissue was obtained from skin biopsies of 13 SSc patients (the location of skin biopsies is the flexure side of the forearm). Disease stage was defined as proposed by Steen and Medsger: early lSSc, disease duration <5 years; late lSSc, disease duration ≥5 years; early dSSc, disease duration <3 years; late dSSc, disease duration ≥3 years; disease duration was from first non-Raynaud symptoms[21, 22]. Eight patients were classified as early SSc (12 ± 7.0 months), five as late SSc (45 ± 8.8 months), 12 were classified as dSSc, and one as lSSc. Four age- and sex-matched healthy tissue samples were obtained with informed consent (three skin biopsies from healthy donors and one tissue from orthopedic surgery).
Tissues were processed and embedded in paraffin by using routine methods. Tissue blocks were serially sectioned to obtain consecutive levels. Sections were stained with hematoxylin and eosin, and immunohistochemistry was performed as previously described by using antibodies to CD3, CD4, CD8, CD20, CD68, IL-17, and Foxp3 (all from Abcam, Cambridge, MA, USA). Immunohistochemical staining was assessed by two independent pathologists without knowledge of patient characteristics. The positive cells in per surface were counted under × 400 magnification, and five randomly selected independent microscopic fields were counted for each sample to ensure that the data were representative and homogeneous.
For detection of Treg cells, PBMCs were stained with fluorescein isothiocyanate (FITC)-conjugated anti-CD4, phycoerythrin (PE)-Cy5-conjugated anti-CD25, and PE-conjugated anti-CD127 (BD Pharmingen, San Jose, CA, USA) according to the manufacturer’s protocol. We gated first on CD4+ T cells and then on CD25+CD127- Treg cells, as previously described. After staining, cells were washed twice and resuspended in FACS solution (phosphate-buffered saline (PBS) with 0.5% bovine serum albumin and 0.02% sodium azide), fixed in PBS containing 1% paraformaldehyde, and analyzed the same day in a FACS-Calibur (BD-Bioscience) followed by analysis with FlowJo (Tree Star).
For detection of Th17 cells, PBMCs were incubated for 4 to 5 hours with 50 ng/ml phorbol 12-myristate 13-acetate (PMA) and 750 ng/ml ionomycin (PI) in the presence of 20 μg/ml Brefeldin A (Sigma-Aldrich, St. Louis, MO, USA) in a tissue-culture incubator at 37°C. Surface staining with PE-Cy5-conjugated anti-CD3 and FITC-conjugated anti-CD8 (BD Pharmingen) was performed for 15 minutes, followed by resuspension in Fixation/Permeabilization solution (Invitrogen, San Diego, CA, USA), according to the manufacturer’s instructions. Intracellular staining of PE-conjugated anti-IL-17 or isotype control was performed according to the manufacturer’s protocol (eBioscience, San Diego, CA, USA). For detection of Th17 cells, we first gated on CD3+ T cells, and analyzed CD8-IL-17+ T cells in a CD3+ gate, as previously described.
Fibroblast isolation, culture, and stimulation
Fibroblasts producing high levels of collagen were isolated from the skin of SSc patients according to our previous modified limiting-dilution method. Isolated fibroblasts were cultured in the presence of 20 ng/ml IL-17 (eBioscience) for the indicated number of days, and the growth of fibroblasts was analyzed by 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. For gene-expression experiments, fibroblasts were cultured in different doses of IL-17 for 48 hours, and collagen 1 and collagen 3 gene expression was analyzed by real-time reverse transcription-polymerase chain reaction (RT-PCR).
To determine the effect of secreted IL-17 on collagen production, PBMCs from patients with active SSc were incubated for 4 to 5 hours with PI (Sigma-Aldrich), and supernatants were collected for later use. Fibroblasts isolated from the skin of SSc patients were cultured for 48 hours, and the culture media was replaced with Dulbecco modified Eagle medium (DMEM; Hyclone, Logan, UT, USA) containing 20% supernatant from the stimulated active SSc PBMC culture, and the cultures were incubated for a further 48 hours. Antibody to IL-17 (eBioscience) was added to some cultures to a final concentration of 20 μg/ml. Culture media with the same doses of PI was used as a vehicle control. Collagen gene expression in fibroblasts was analyzed with real-time RT-PCR, and collagen secretion was analyzed by enzyme-linked immunosorbent assay (ELISA).
In similar experiments, isolated CD4+CD161+CD196+ Th17 cells[24, 25] (eBioscience) were incubated for 4 to 5 hours with PI, and the supernatants were collected. Fibroblasts were cultured for 48 hours, and the culture media was replaced with DMEM (Hyclone) containing 20% supernatant from Th17 cells (4 × 105 cells) from patients with active SSc or healthy controls. Antibody to IL-17 was added to some cultures to a final concentration of 20 μg/ml. After incubation for another 48 hours, collagen secretion was analyzed with ELISA.
Sera were collected from SSc patients and healthy controls and frozen at -80°C until needed. Serum concentrations of IL-17 were determined with ELISA (R&D, Minneapolis, MN, USA). In some experiments, isolated PBMCs were cultured and stimulated with PI (Sigma-Aldrich) for 5 hours before measurement of IL-17 in the supernatants.
Analysis of cytokine and transcription factor mRNA expression
Total RNA was purified with Trizol reagent (Invitrogen). cDNAs were synthesized by using ReverTra Ace-α- Kit (Toyobo), and mRNA expression was determined by using a SYBR green kit (Toyobo). The 2-ΔΔCt method was used to normalize transcription to β-actin and to calculate the fold induction relative to controls. The following primer pairs were used: Hum 18S, forward GCCCGAAGCGTTTACTTTGA and reverse TCCATTATTCCTAGCTGCGGTATC; Hum Foxp3, forward GAAACAGCACATTCCCAGAGTTC and reverse ATGGCCCAGCGGATGAG; Hum retinoic acid-related orphan receptor-gamma t (RORγt), forward TGAGAAGGACAGGGAGCCAA and reverse CCACAGATTTTGCAAGGGATCA; Hum IL-17, forward CAACCGATCCACCTCACCTT and reverse GGCACTTTGCCTCCCAGAT; Hum COL1, forward GTTGTGCGATGACGTGATCTGTGA and reverse TTCTTGGTCGGTGGGTGACTCTG; Hum COL3, forward CGGGTGAGAAAGGTGAAGGAGG and reverseAGGACCAGGAAGACCACGAGCA.
Results were expressed as mean ± standard deviation. Statistical significance was determined by analysis of variance for comparisons of multiple means followed by the Bonferroni post hoc test or the Student t test and the Mann-Whitney U test. Correlations were determined with Spearman ranking.
Inflammatory cell profiles in skin of SSc patients
These data indicate that complex inflammatory cell infiltration is involved in the course of early SSc and that the inflammation reaction decreases in later stages of disease.
Increased infiltration of IL-17+ and Foxp3+ lymphocytes in the skin of patients with early SSc
The percentage of Th17 cells is expanded in SSc patients, but the percentage of Treg cells is not significantly affected
Treg cells play a key role in peripheral immune tolerance and prevent the occurrence of autoimmune disease[13, 14]. In this study, Treg cells were quantified by CD4+CD25+CD127- T cells. The percentage of CD4+CD25+CD127- T cells decreased slightly, but not significantly, in patients with active SSc (6.25 ± 1.22%, n = 13) compared with patients with stable disease (6.47 ± 1.49%, P > 0.05, n = 32) and healthy controls (7.14 ± 1.61%, P > 0.05, n = 24; Figure 3F). The percentage of Treg cells was not related to disease activity and the expansion of Th17 cells in patients with active SSc (data not shown). Expression of Foxp3, a transcription factor in Treg cells, was not significantly different in patients with active SSc compared with patients with stable disease and healthy controls (Figure 3D).
Th17-derived IL-17 contributes to fibroblast proliferation and collagen production
We found that IL-17 alone could promote fibroblast growth as measured by MTT assay (See Additional file1: Figure S1A). Furthermore, IL-17 could induce collagen 1 and collagen 3 mRNA expression in fibroblasts in a dose-dependent manner (See Additional file1: Figure S1B). These data indicated that IL-17 could induce fibroblast growth and collagen production. To determine further whether IL-17 derived from patients with active SSc can induce fibroblast growth and collagen production, we prepared supernatants from stimulated PBMCs of patients with active SSc in culture, and investigated its effect on the expression of collagen 1 and collagen 3 in fibroblasts. We found that culture supernatants from PBMCs of patients with active SSc promoted both mRNA expression and protein secretion of collagen 1 and collagen 3 in fibroblasts (Figure 4C, D). More notably, neutralization of IL-17 in the culture medium inhibited mRNA expression and protein secretion of collagen 1 and collagen 3 (Figure 4C, D). Furthermore, our data showed that supernatants from stimulated PBMCs of active SSc patients could dose- and time-dependently induce the collagen 1 and collagen 3 mRNA (See Additional file2: Figure S2). These data indicate that fibroblasts are responsive to stimulation by IL-17 produced by PBMCs derived from SSc patients.
In addition, IL-17 not only induced collagen secretion, but our data also showed that IL-17 could promote the collagen synthesis (See Additional file3: Figure S3A). Further data showed that IL-17 could promote ERK phosphorylation in fibroblast, and ERK phosphorylation inhibitor could block IL-17-iduced fibroblast proliferation and collagen production (See Additional file3: Figure S3B, C). These data suggest that the ERK signal pathway might be involved in the IL-17-mediated fibrosis in SSc patients.
The pathologic hallmark of SSc is excessive collagen deposition and microvascular injury. However, the mechanisms that lead to these changes remain largely unknown. An early skin mononuclear cell infiltrate consisting primarily of T cells and macrophages has been demonstrated. Moreover, the degree of mononuclear cell infiltration in the skin of patients with SSc has been shown to correlate well with both the degree and progression of skin thickening. Several lines of evidence suggest that T cells are important in the pathogenesis of SSc: first, T cells infiltrate skin early, before any evidence of fibrosis; second, an increased number of activated T cells is found in blood and skin lesions; third, T cells producing cytokines can induce fibroblast collagen production; fourth, T cells are necessary for antibody production; and fifth, treatments directed against T cells ameliorate systemic sclerosis. These results bring the role of T cells in the pathogenesis of SSc to the forefront of the various mechanisms that may contribute to the pathogenesis of the disease. Although the role of immune dysfunction in the pathogenesis of SSc is generally accepted and strong evidence exists for the participation of T cells in the pathogenesis of this disease, the traditional Th1/Th2 paradigm has not been very helpful in explaining several aspects of the illness.
In our study, we showed that patients with active SSc had increased levels of circulating Th17 cells. In keeping with these observations, Th17 cell–derived IL-17 was significantly higher in the serum of SSc patients compared with controls. In addition, increased infiltration of IL-17+ cells was present in involved skin of patients with early SSc. These data imply that Th17 cells are globally expanded in patients with active SSc rather than being redistributed. Although Th17 cells have been reported to account for several autoimmune diseases[29–31], the role of these cells in the course of fibrosis of SSc is not clearly understood. Our data showed that IL-17 alone could induce fibroblast growth and collagen gene expression and protein secretion, IL-17 derived from PBMCs and Th17 cells of patients with active SSc could promote collagen gene expression and protein production in fibroblasts, and neutralization of IL-17 in vitro could block collagen production. Furthermore, Th17 cells isolated from active SSc could promote fibroblast growth and collagen production. IL-17 not only induced collagen secretion, but promote fibroblast proliferation and the collagen synthesis (See Additional file3: Figure S3). These data indicate that Th17 cell-derived IL-17 may be involved in the fibrosis of SSc patients.
Treg cells are critical in maintaining self-tolerance and preventing autoimmunity[13, 14] and have been implicated in the pathogenesis of several autoimmune diseases. Our previous study also showed that Treg cells were depleted in patients with active SLE, which might be related to the expansion of Th17 cells. In SSc patients, some reports have shown that although the number of Treg cells is markedly increased[4, 33], these Treg cells have a diminished capacity to control CD4 effector T cells. Our study showed that the number of circulating Treg cells decreased slightly, but not significantly, in patients with active SSc, which is partially consistent with previous findings that the percentage of Treg cells is decreased in SSc patients. Treg cells dynamically change with the development of disease activity, and the enrolment of SSc patients with different disease activities might contribute to the discrepancy in the percentage of Treg cells among different studies. A major limitation of previous studies was that they did not determine whether Treg cells infiltrated the skin of patients with different stage of SSc, and the numbers of Treg cells that localized with skin inflammation was not clear. Our study showed that Foxp3+ Treg cells could be detected more frequently in both the epidermis and dermis of patients with early SSc compared with patients with stable SSc and healthy controls. Our unpublished data showed that the isolated circulating Treg cells did not affect fibroblast growth and collagen production. The upregulation of Foxp3+ cells in the skin of patients with early SSc may reflect a regulatory feedback mechanism to restore cellular tolerance and ameliorate harmful autoimmune responses.
One of the strengths of this study is the ability to analyze inflammatory cell subsets in involved skin of SSc patients with different clinical stages of disease. This enabled us to evaluate which complex inflammatory cell groups might be dynamically involved in the pathogenesis of SSc. Our data showed that Th17 cells were globally expanded in patients with active SSc and that Th17 cell-derived IL-17 might be related to the fibrosis of SSc. Further studies into the role of Th17 cells and IL-17 in fibrosis, as well as their effects in affected cells and tissue, are warranted. Furthermore, Th17 cell are only one of the factors for the fibrosis in SSc; more study should be done to make clear other lymphocytes or cytokines in the pathogenesis of fibrosis of SSc.
Taken together, our data suggest that the pathophysiology of SSc might be linked to the expansion of Th17 cells and that Th17-derived IL-17 may play a key role in the fibrotic course of SSc. These insights open novel avenues for research aimed at identifying pathogenic pathways and therapeutic targets.
Dulbecco modified Eagle medium
diffuse cutaneous SSc
enzyme-linked immunosorbent assay
limited cutaneous SSc
peripheral blood mononuclear cells
phorbol 12-myristate 13-acetate
reverse transcription-polymerase chain reaction
T helper 17 cells
We thank S.H. Sun and H.Y. Zeng for technical assistance and L.B. Zhu, D. G, and X.R. Yang for helpful discussions. This work was supported by grants from the National Natural Science Foundation of China (30872274; 81000693; 30901291), Medical Guide Project from Shanghai Municipal Science and Technology (134119a8400).
- Varga J, Abraham D: Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007, 117: 557-567. 10.1172/JCI31139.View ArticlePubMedPubMed CentralGoogle Scholar
- Baraut J, Michel L, Verrecchia F, Farge D: Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmun Rev. 2010, 10: 65-73. 10.1016/j.autrev.2010.08.003.View ArticlePubMedGoogle Scholar
- Sakkas LI, Platsoucas CD: Is systemic sclerosis an antigen-driven T cell disease?. Arthritis Rheum. 2004, 50: 1721-1733. 10.1002/art.20315.View ArticlePubMedGoogle Scholar
- Giovannetti A, Rosato E, Renzi C, Maselli A, Gambardella L, Giammarioli AM: Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis: correlations with disease severity and phenotypes. Clin Immunol. 2010, 137: 122-133. 10.1016/j.clim.2010.06.004.View ArticlePubMedGoogle Scholar
- Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005, 6: 1123-1132. 10.1038/ni1254.View ArticlePubMedGoogle Scholar
- Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005, 6: 1133-1141. 10.1038/ni1261.View ArticlePubMedPubMed CentralGoogle Scholar
- Nakashima T, Jinnin M, Yamane K, Honda N, Kajihara I, Makino T: Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. J Immunol. 2012, 188: 3573-3583. 10.4049/jimmunol.1100591.View ArticlePubMedGoogle Scholar
- Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y: Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum. 2000, 43: 2455-2463. 10.1002/1529-0131(200011)43:11<2455::AID-ANR12>3.0.CO;2-K.View ArticlePubMedGoogle Scholar
- Radstake TR, van Bon L, Broen J, Hussiani A, Hesselstrand R, Wuttge DM: The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One. 2009, 4: e5903-10.1371/journal.pone.0005903.View ArticlePubMedPubMed CentralGoogle Scholar
- Rodriguez-Reyna TS, Furuzawa-Carballeda J, Cabiedes J, Fajardo-Hermosillo LD, Martinez-Reyes C, Diaz-Zamudio M: Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study. Rheumatol Int. 2011, 32: 2653-2660.View ArticlePubMedGoogle Scholar
- Truchetet ME, Brembilla NC, Montanari E, Allanore Y, Chizzolini C: Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res Ther. 2011, 13: R166-10.1186/ar3486.View ArticlePubMedPubMed CentralGoogle Scholar
- Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X: Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009, 60: 1472-1483. 10.1002/art.24499.View ArticlePubMedGoogle Scholar
- Shevach EM: Regulatory T, cells in autoimmmunity. Annu Rev Immunol. 2000, 18: 423-449. 10.1146/annurev.immunol.18.1.423.View ArticlePubMedGoogle Scholar
- Sakaguchi S: Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004, 22: 531-562. 10.1146/annurev.immunol.21.120601.141122.View ArticlePubMedGoogle Scholar
- Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M: Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science. 2007, 317: 256-260. 10.1126/science.1145697.View ArticlePubMedGoogle Scholar
- Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006, 441: 235-238. 10.1038/nature04753.View ArticlePubMedGoogle Scholar
- Khoury SJ: Th17 and Treg balance in systemic sclerosis. Clin Immunol. 2011, 139: 231-232. 10.1016/j.clim.2011.03.014.View ArticlePubMedGoogle Scholar
- Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980, 23: 581-590. 10.1002/art.1780230510.View ArticleGoogle Scholar
- LeRoy EC, Medsger TA: Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001, 28: 1573-1576.PubMedGoogle Scholar
- Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, D’Angelo S: European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis. 2001, 60: 592-598. 10.1136/ard.60.6.592.View ArticlePubMedPubMed CentralGoogle Scholar
- Mathian A, Parizot C, Dorgham K, Trad S, Arnaud L, Larsen M: Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. Ann Rheum Dis. 2012, 71: 1227-1234. 10.1136/annrheumdis-2011-200709.View ArticlePubMedGoogle Scholar
- Steen VD, Medsger TA: Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000, 43: 2437-2444. 10.1002/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U.View ArticlePubMedGoogle Scholar
- Zhu L, Gao D, Yang J, Li M: Characterization of the phenotype of high collagen-producing fibroblast clones in systemic sclerosis, using a new modified limiting-dilution method. Clin Exp Dermatol. 2012, 37: 395-403. 10.1111/j.1365-2230.2011.04254.x.View ArticlePubMedGoogle Scholar
- Sollazzo D, Trabanelli S, Curti A, Vianelli N, Lemoli RM, Catani L: Circulating CD4+ CD161+ CD196+ Th17 cells are not increased in immune thrombocytopenia. Haematologica. 2011, 96: 632-634. 10.3324/haematol.2010.038638.View ArticlePubMedPubMed CentralGoogle Scholar
- Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A: Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol. 2007, 8: 639-646. 10.1038/ni1467.View ArticlePubMedGoogle Scholar
- Korn T, Bettelli E, Oukka M, Kuchroo VK: IL-17 and Th17 Cells. Annu Rev Immunol. 2009, 27: 485-517. 10.1146/annurev.immunol.021908.132710.View ArticlePubMedGoogle Scholar
- Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ: The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006, 126: 1121-1133. 10.1016/j.cell.2006.07.035.View ArticlePubMedGoogle Scholar
- Roumm AD, Whiteside TL, Medsger TA, Rodnan GP: Lymphocytes in the skin of patients with progressive systemic sclerosis: quantification, subtyping, and clinical correlations. Arthritis Rheum. 1984, 27: 645-653. 10.1002/art.1780270607.View ArticlePubMedGoogle Scholar
- Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J: Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007, 445: 648-651. 10.1038/nature05505.View ArticlePubMedGoogle Scholar
- Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P, Wedderburn LR: Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum. 2008, 58: 875-887. 10.1002/art.23291.View ArticlePubMedPubMed CentralGoogle Scholar
- Louten J, Boniface K, de Waal MR: Development and function of TH17 cells in health and disease. J Allergy Clin Immunol. 2009, 123: 1004-1011. 10.1016/j.jaci.2009.04.003.View ArticlePubMedGoogle Scholar
- Yang J, Yang X, Zou H, Chu Y, Li M: Recovery of the immune balance between Th17 and regulatory T cells as a treatment for systemic lupus erythematosus. Rheumatology. 2011, 50: 1366-1372. 10.1093/rheumatology/ker116.View ArticlePubMedGoogle Scholar
- Slobodin G, Ahmad MS, Rosner I, Peri R, Rozenbaum M, Kessel A: Regulatory T cells (CD4(+)CD25(bright)FoxP3(+)) expansion in systemic sclerosis correlates with disease activity and severity. Cell Immunol. 2010, 261: 77-80. 10.1016/j.cellimm.2009.12.009.View ArticlePubMedGoogle Scholar
- Radstake TR, van Bon L, Broen J, Wenink M, Santegoets K, Deng Y: Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression. PLoS One. 2009, 4: e5981-10.1371/journal.pone.0005981.View ArticlePubMedPubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.